Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
Anna Torrent CatarineuMireia MorgadesOlga García-CalduchMaría Paz Queipo de LlanoPau MontesinosIrene NavarroJesús María Hernández-RivasAbelardo Bárez-GarcíaJosé González-CamposItziar OiartzabalMarta ValeroMarta CerveraTeresa Zudaire RipaManuel Albors-FerreiroOriana Lopez-GodinoCristina Gil-CortésLucía VillalónRaquel SaldañaJosep-María RiberaPublished in: European journal of haematology (2023)
Our study showed slightly inferior outcomes of the pivotal trial probably due to poorer risk factors and late onset of IO therapy of recruited patients. Our results support early use of IO in relapsed/refractory ALL patients.
Keyphrases
- acute lymphoblastic leukemia
- end stage renal disease
- late onset
- risk factors
- chronic kidney disease
- newly diagnosed
- acute myeloid leukemia
- prognostic factors
- peritoneal dialysis
- clinical trial
- early onset
- diffuse large b cell lymphoma
- study protocol
- metabolic syndrome
- stem cells
- allogeneic hematopoietic stem cell transplantation
- type diabetes
- hodgkin lymphoma
- adipose tissue
- phase iii
- mesenchymal stem cells
- bone marrow